Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115516) titled 'Disitamab Vedotin and Adebrelimab in combination with SOX in the perioperative treatment of HER2-expressing Locally Advanced Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma: A Prospective, Single-Arm Phase II Study' on Dec. 26, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences
Condition:
Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-02-28
Target Sample Size: ADC plus immunotherapy group:39;
Countrie...